The strategies underpinning the development of this novel merged format are several. First and foremost, current approaches to neurodegenerative diseases have rapidly evolved toward the inclusion of numerous high-tech and/or high level computational strategies that have been refined only very recently. Yet, a working understanding of these new “big data” technolologies in order to follow, participate in, or lead state of the art neurological investigation,
Multiscale integrated approaches, human induced pluripotent stem cell (iPSC) systems, brain organoids, and network level neuromodulation are but a few examples of the methods now applied toward elucidation of mechanisms underlying proteinopathies and neurodegenerative diseases and toward the targeting of those mechanisms in drug development and using non-invasive intervention approaches.
* The CSHAHND program will begin with ~ 3 full days of state-of-the-art reviews of high tech/big data/iPSCs/organoids/neuromodulation methodology delivered by faculty who are experts currently working in and/or playing leadership roles in each area. Many of these faculty will accomplish this challenge by delivery both didactic material as well as their newest unpublished data, all of which will be conducted in highly interactive sessions, moderated by CSHAHND directors and/or faculty.
* Where possible, we will include examples of interventions and/or compounds that have been judged to provide meaningful clinical benefits to proteopathy and/or neurodegenerative diseases. Experts from industry and academia will discuss these examples of interventions that now, in some parts of the world, have secured the regulatory approval of their governments.
* The remainder of the program will be led by experts in each of several key disease areas will present both an overview of the status of understanding and/or intervening in each disease and examples of the current strategies being employed by his/her laboratory research group. These diseases will include (among others):
o Alzheimer's disease, amyloid angiopathy, and amyloid conformer toxicity
o Vascular dementia (aka VCID, for “vascular cognitive impairment and dementia”)
o Genetic, sporadic and post-traumatic tauopathies (e.g., frontotemporal dementia and chronic traumatic encephalopathy)
o Typical and variant prionopathies of humans and other mammals (e.g., typical and variant Creutzfeldt Jakob disease, bovine spongiform encephalopathy, chronic wasting disease)
o Parkinson’s disease and other synucleinopathies (e.g., Lewy body dementia)
o Huntington’s disease and other trinucleotide repeat diseases
o Retinal degeneration
Speakers will be encouraged to remain at the CSHA site in Suzhou for as many days as possible and to attend and join in the discussions at their leisure. In so doing, the Directors aim to offer to our international audience the most in-depth program and broadest possible representation of strategies and opinions that may vary widely.
Attendees will also have the opportunity to share their ideas, results, and/or both with our faculty of experts. Each attendee is encouraged to arrive having mentally prepared to present his or her ideas and/or progress and/or challenges in highly informal “chalk talk” sessions. Sufficient time will be set aside for each attendee to present such a “chalk talk”.
We look forward to welcoming the directors, faculty and attendee participants to the Cold Spring Harbor Asia campus in Suzhou in the spring of 2020.
2021 Invited lecturers include (Lecturer, Affiliation, Region):
Zoe Arvanitakis, RUSH, Chicago IL
Karen Hsiao Ashe, Univ MN, Minneapolis MN
Tim Bartels, UCL, London UK
Diane Chan, MIT, Cambridge MA & MGH, Boston, MA
John Collinge, UCL, London UK
Joel Dudley, ISMMS, New York NY
Michelle Ehrlich, ISMMS, New York NY
Li Gan, Weill Cornell, New York NY
Sam Gandy, ISMMS, New York City, NY
Aaron Gitler, Stanford Univ, Palo Alto CA
Soyon Hong, UCL, London UK
Ephraim Katz, Pharma Consultant, New York NY
Jonathan Kipnis, Univ VA, Charlottesville VA
Manolis Kellis, MIT, Cambridge MA
Kenneth Kosik, UC Santa Barbara, Santa Barbara CA
Blair Leavitt, Univ Brit Columbia, Vancouver BC
Efrat Levy, NYU, New York NY & NKI, Orangeburg NY
Colin Masters, Florey Inst, Univ Melb, Melbourne VIC
Scott Noggle, NYSCF, New York NY
Leonard Petrucelli, Mayo, Jacksonville FL
Wenjuan Zhang, MRC, Cambridge UK
Annabelle Singer, Georgia Tech & Emory Univ, Atlanta GA
Li-Huei Tsai, MIT, Cambridge MA
Stephen Tsang, Columbia Univ, New York NY
John van Swieten, Erasmus MC, Rotterdam, Netherlands
Tracy Young-Pearse, Harvard, Cambridge MA & BWH, Boston MA
Yingyue Zhou, Washington Univ, St Louis MO
REGULAR PRICING (INCLUDING TUITION, BOARD AND LODGING): 1300 USD
Please note stipends are available to offset tuition costs. No payment is due until the selection decisions are made but any applicant requiring support should request this in writing during the online application. The admissions process is need-blind, your financial situation will not be considered before admission decisions are made.